Concurrent loss of the Y chromosome in cancer and T cells impacts outcome [snRNA-seq]
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
PROVIDER: GSE290588 | GEO | 2025/03/10
REPOSITORIES: GEO
Similar Datasets
Project description:Loss of the Y chromosome (LOY) in peripheral blood mononuclear cells (PBMCs) is the most common somatic alteration in normal men and is associated with greater mortality from epithelial cancers. In tumors, epithelial cell LOY is also associated with worse survival. This raises the fundamental question of whether a relationship between LOY in PBMCs, PBMC-derived immune cells, and cancer cells exists, and if so, what the consequences are. We addressed this through a comprehensive pan-cancer analysis of bulk and single-cell RNA sequencing data from 29 distinct human tumor types, and from autochthonous and syngeneic murine models of cancer. In both human and murine tumors, malignant epithelial cells had the highest LOY prevalence, which was associated with significant phenotypic changes. Remarkably, LOY was also found in stromal and immune cells of the tumor microenvironment (TME) of both species, with the presence of LOY in malignant epithelial cells predicting LOY in benign cells. In addition, LOY was correlated between paired tumor and PBMC samples from patients. Among benign cells, LOY drove the strongest phenotypic shift in CD4+ T and CD8+ T cells, with both showing signs of immunosuppression. The magnitudes of LOY in epithelial cells, CD4+ T cells, and CD8+ T cells were independent predictors of overall survival, with tumors exhibiting concurrent epithelial and T cell LOY having the worst outcomes. These findings provide a novel model linking LOY in immune and malignant epithelial cells and explain in part why LOY in PBMCs and tumors are both associated with greater cancer mortality.
2025-03-10 | GSE290587 | GEO
Project description:Loss of the Y chromosome (LOY) in peripheral blood mononuclear cells (PBMCs) is the most common somatic alteration in normal men and is associated with greater mortality from epithelial cancers. In tumors, epithelial cell LOY is also associated with worse survival. This raises the fundamental question of whether a relationship between LOY in PBMCs, PBMC-derived immune cells, and cancer cells exists, and if so, what the consequences are. We addressed this through a comprehensive pan-cancer analysis of bulk and single-cell RNA sequencing data from 29 distinct human tumor types, and from autochthonous and syngeneic murine models of cancer. In both human and murine tumors, malignant epithelial cells had the highest LOY prevalence, which was associated with significant phenotypic changes. Remarkably, LOY was also found in stromal and immune cells of the tumor microenvironment (TME) of both species, with the presence of LOY in malignant epithelial cells predicting LOY in benign cells. In addition, LOY was correlated between paired tumor and PBMC samples from patients. Among benign cells, LOY drove the strongest phenotypic shift in CD4+ T and CD8+ T cells, with both showing signs of immunosuppression. The magnitudes of LOY in epithelial cells, CD4+ T cells, and CD8+ T cells were independent predictors of overall survival, with tumors exhibiting concurrent epithelial and T cell LOY having the worst outcomes. These findings provide a novel model linking LOY in immune and malignant epithelial cells and explain in part why LOY in PBMCs and tumors are both associated with greater cancer mortality.
2025-03-18 | GSE290115 | GEO
Project description:Loss of the Y chromosome (LOY) in peripheral blood mononuclear cells (PBMCs) is the most common somatic alteration in normal men and is associated with greater mortality from epithelial cancers. In tumors, epithelial cell LOY is also associated with worse survival. This raises the fundamental question of whether a relationship between LOY in PBMCs, PBMC-derived immune cells, and cancer cells exists, and if so, what the consequences are. We addressed this through a comprehensive pan-cancer analysis of bulk and single-cell RNA sequencing data from 29 distinct human tumor types, and from autochthonous and syngeneic murine models of cancer. In both human and murine tumors, malignant epithelial cells had the highest LOY prevalence, which was associated with significant phenotypic changes. Remarkably, LOY was also found in stromal and immune cells of the tumor microenvironment (TME) of both species, with the presence of LOY in malignant epithelial cells predicting LOY in benign cells. In addition, LOY was correlated between paired tumor and PBMC samples from patients. Among benign cells, LOY drove the strongest phenotypic shift in CD4+ T and CD8+ T cells, with both showing signs of immunosuppression. The magnitudes of LOY in epithelial cells, CD4+ T cells, and CD8+ T cells were independent predictors of overall survival, with tumors exhibiting concurrent epithelial and T cell LOY having the worst outcomes. These findings provide a novel model linking LOY in immune and malignant epithelial cells and explain in part why LOY in PBMCs and tumors are both associated with greater cancer mortality.
2025-03-18 | GSE290114 | GEO
Project description:Loss of the Y chromosome (LOY) in peripheral blood mononuclear cells (PBMCs) is the most common somatic alteration in normal men and is associated with greater mortality from epithelial cancers. In tumors, epithelial cell LOY is also associated with worse survival. This raises the fundamental question of whether a relationship between LOY in PBMCs, PBMC-derived immune cells, and cancer cells exists, and if so, what the consequences are. We addressed this through a comprehensive pan-cancer analysis of bulk and single-cell RNA sequencing data from 29 distinct human tumor types, and from autochthonous and syngeneic murine models of cancer. In both human and murine tumors, malignant epithelial cells had the highest LOY prevalence, which was associated with significant phenotypic changes. Remarkably, LOY was also found in stromal and immune cells of the tumor microenvironment (TME) of both species, with the presence of LOY in malignant epithelial cells predicting LOY in benign cells. In addition, LOY was correlated between paired tumor and PBMC samples from patients. Among benign cells, LOY drove the strongest phenotypic shift in CD4+ T and CD8+ T cells, with both showing signs of immunosuppression. The magnitudes of LOY in epithelial cells, CD4+ T cells, and CD8+ T cells were independent predictors of overall survival, with tumors exhibiting concurrent epithelial and T cell LOY having the worst outcomes. These findings provide a novel model linking LOY in immune and malignant epithelial cells and explain in part why LOY in PBMCs and tumors are both associated with greater cancer mortality.
2025-03-18 | GSE290113 | GEO
Project description:Loss of the Y chromosome (LOY) in peripheral blood mononuclear cells (PBMCs) is the most common somatic alteration in normal men and is associated with greater mortality from epithelial cancers. In tumors, epithelial cell LOY is also associated with worse survival. This raises the fundamental question of whether a relationship between LOY in PBMCs, PBMC-derived immune cells, and cancer cells exists, and if so, what the consequences are. We addressed this through a comprehensive pan-cancer analysis of bulk and single-cell RNA sequencing data from 29 distinct human tumor types, and from autochthonous and syngeneic murine models of cancer. In both human and murine tumors, malignant epithelial cells had the highest LOY prevalence, which was associated with significant phenotypic changes. Remarkably, LOY was also found in stromal and immune cells of the tumor microenvironment (TME) of both species, with the presence of LOY in malignant epithelial cells predicting LOY in benign cells. In addition, LOY was correlated between paired tumor and PBMC samples from patients. Among benign cells, LOY drove the strongest phenotypic shift in CD4+ T and CD8+ T cells, with both showing signs of immunosuppression. The magnitudes of LOY in epithelial cells, CD4+ T cells, and CD8+ T cells were independent predictors of overall survival, with tumors exhibiting concurrent epithelial and T cell LOY having the worst outcomes. These findings provide a novel model linking LOY in immune and malignant epithelial cells and explain in part why LOY in PBMCs and tumors are both associated with greater cancer mortality.
2025-03-18 | GSE290112 | GEO
Project description:Ovarian cancer is common among women. Cancer in ovaries can arise from three different tissues, epithelial, germ and stromal cells. Majority of ovarian cancer arise from epithelial tissues. However, cancer in the germ cells or stromal cells are histologically, genetically and clinically heterogeneous, which result in a challenge in terms of treatment. In this study, we generated sRNA libraries of germ cell tumors (7 benign and 2 malignant) as well as 3 stromal tumors. In particular, we analyzed the miRNA profile of these tumors and found that malignant ovarian germ cell tumors (OGCT) are genetically distinct from benign OGCT and sex cord-stromal tumors (SCST). We detected several miRNAs that were deregulated in malignant OGCT compared to benign and SCST and fewer deregulated miRNAs between benign OGCT and SCST. However, we were still able to detect several deregulated miRNAs between benign OGCT and SCST.
2017-09-01 | GSE98536 | GEO
Project description:We analyzed gene expression in human peripheral blood mononuclear cells (PBMCs) from breast cancer patients, patients with benign breast abnormalities, healthy cancer-free individuals as well as patients with other types of cancer (gastrointestinal and brain cancers). Peripheral blood mononuclear cell (PBMC) samples were collected from women with a suspect initial mammogram prior to undergoing a diagnostic biopsy procedure to determine whether the detected abnormality was benign or malignant. In total, we collected blood from 57 women with a diagnosis of breast cancer and 37 with a benign diagnosis. We also collected blood from 31 women with normal initial mammograms as negative controls and 15 breast cancer patients following surgery. All breast cancer patient samples were collected at the Duke University Medical Center (DUMC) under an institutional review board (IRB)-approved protocol (Duke eIRB#12025) after obtaining informed consent and were provided by Dr. Jeffrey Marks. PBMC samples from patients with various gastrointestinal cancers (n=15) were colelcted and stored at DUMC under IRB-approved protocols (Duke eIRB#12010 and 12025) and were provided by Dr. Jeffrey Marks. Peripheral blood leukocyte samples from patients with brain tumors (n=7) were provided by Dr. John Sampson and were collected by leukapheresis under Duke eIRB#00003877 and #00009403.
2011-03-01 | E-GEOD-27562 | biostudies-arrayexpress
Project description:Epithelial ovarian cancer is morphologically and clinically heterogeneous. Transcriptional profiling has revealed molecular subtypes (referred to as M-bM-^@M-^\C-signaturesM-bM-^@M-^]) that correlate to biological as well as clinical features. We aimed to determine gene expression differences between malignant, benign and borderline serous ovarian tumors, and to investigate similarities to the intrinsic molecular subtypes of breast cancer. Global gene expression profiling was performed using Illumina's HT12 Bead Arrays and applied to 59 fresh-frozen ovarian tumors. SAM analysis revealed enrichment of cell cycel processes among the malignant tumors, in line with malignant tumors being highly proliferative. The borderline tumors were split between the malignant and benign tumor clusters, indicating that borderline tumors have both malignant and benign features. Furthermore, nearest centroid classification was performed applying previously published gene profiles for the ovarian cancer C-signatures and the intrinsic breast cancer subtypes, respectively, and showed significant correlations between the malignant serous tumors and the highly aggressive C1, C2 and C4 ovarian cancer signatures, and the basal-like breast cancer subtype. The benign and borderline serous tumors together were significantly correlated to the normal-like breast cancer subtype and the ovarian cancer C3 signature. The borderline tumors, on the other hand, correlated significantly to the Luminal A breast cancer subtype. These findings remained when analyzed in a large, independent dataset. The data in this study link the transcriptional profiles of serous ovarian cancer to the intrinsic molecular subtypes of breast cancer, in line with the shared clinical and molecular features between high-grade serous ovarian cancer and basal-like breast cancer, including an aggressive phenotype, frequent TP53 mutations and a high degree of genomic instability, and suggest that biomarkers and targeted therapies may overlap between these subsets of ovarian and breast cancers. Finally, the link between benign and borderline ovarian cancer and luminal breast cancer may indicate endocrine responsiveness in a subset of ovarian cancers. Total RNA obtained from serous ovarian adenocarcinomas, adenomas and borderline tumors. Gene expression profiling using Illumina's HT12 v4 bead arrays. Application of ovarian cancer molecular subtypes and intrinsic breast cancer subtypes using nearest centroid classification. KRAS and BRAF mutation analyses in the malignant and borderline tumors.
2014-08-15 | E-GEOD-57477 | biostudies-arrayexpress
Project description:Tissue of the breast is heterogeneous, consisting of a variety of cell types and connective tissue. This heterogeneity is also present in breast tumors and will complicate proteomic analysis, as it is not always clear whether a signal originates from the stromal environment, from normal epithelial or tumor cells. Here we microdissected a variety of cell types and stroma from benign and malignant breast tissues. We compared proteomic differences between these tissues, both from cells of epithelial origin and the stromal environment. Differences in protein abundances corresponded with several hallmarks of cancer, including loss of cell adhesion, transformation to a migratory phenotype, and enhanced energy metabolism. Furthermore, despite enriching for (tumor) epithelial cells, many changes to the extracellular matrix were detected in microdissected cells of epithelial origin. The stromal compartment was heterogeneous and richer in the number of fibroblast and immune cells in malignant sections, compared to benign tissue sections. Although this heterogeneity complicated detection of differentially abundant proteins, several markers were exclusively detected in stroma. However, as heterogeneity in the stroma is more difficult to be reduced through microdissection, comparative analysis was most informative in microdissected cells of epithelial origin, and provided a relatively complete picture of malignant transformations.
2017-01-11 | PXD003632 | Pride
Project description:Epithelial ovarian cancer is morphologically and clinically heterogeneous. Transcriptional profiling has revealed molecular subtypes (referred to as “C-signatures”) that correlate to biological as well as clinical features. We aimed to determine gene expression differences between malignant, benign and borderline serous ovarian tumors, and to investigate similarities to the intrinsic molecular subtypes of breast cancer. Global gene expression profiling was performed using Illumina's HT12 Bead Arrays and applied to 59 fresh-frozen ovarian tumors. SAM analysis revealed enrichment of cell cycel processes among the malignant tumors, in line with malignant tumors being highly proliferative. The borderline tumors were split between the malignant and benign tumor clusters, indicating that borderline tumors have both malignant and benign features. Furthermore, nearest centroid classification was performed applying previously published gene profiles for the ovarian cancer C-signatures and the intrinsic breast cancer subtypes, respectively, and showed significant correlations between the malignant serous tumors and the highly aggressive C1, C2 and C4 ovarian cancer signatures, and the basal-like breast cancer subtype. The benign and borderline serous tumors together were significantly correlated to the normal-like breast cancer subtype and the ovarian cancer C3 signature. The borderline tumors, on the other hand, correlated significantly to the Luminal A breast cancer subtype. These findings remained when analyzed in a large, independent dataset. The data in this study link the transcriptional profiles of serous ovarian cancer to the intrinsic molecular subtypes of breast cancer, in line with the shared clinical and molecular features between high-grade serous ovarian cancer and basal-like breast cancer, including an aggressive phenotype, frequent TP53 mutations and a high degree of genomic instability, and suggest that biomarkers and targeted therapies may overlap between these subsets of ovarian and breast cancers. Finally, the link between benign and borderline ovarian cancer and luminal breast cancer may indicate endocrine responsiveness in a subset of ovarian cancers.
2014-08-15 | GSE57477 | GEO